CitroTech Inc. (CITR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Transcript

CitroTech CEO Wesley Bolsen presented at the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 10, 2026, highlighting the company’s claim to the first-ever EPA Safer Choice-recognized long-term fire inhibitor and positioning CitroTech as the only NYSE-listed pure-play in wildfire prevention/protection. Bolsen emphasized product applicability to wood products, lumber and building materials and underscored his prior exit (LaderaTech sold to Perimeter Solutions) and Perimeter leadership experience; no revenue, guidance or financial metrics were disclosed, suggesting limited near-term market-moving impact.

Analysis

The competitive dynamic is set up as a classic incumbent-disruptor confrontation: a differentiated chemistry can win share not just by efficacy but via insurance-driven demand shifts. Expect adoption to cluster by large municipal and utility procurement cycles — meaningful revenue inflection points will come in discrete tranche wins (state/utility contracts) rather than smooth monthly adoption, concentrating upside into identifiable RFP windows over the next 6–18 months.

Second-order supply-chain effects matter more than product efficacy alone. Scaling to aerial and bulk ground applications requires multi-tonne continuous-feed manufacturing, specialty feedstocks and distributed storage/handling; any single bottleneck (reactor capacity, specialty salt supply, or logistics for remote staging) can delay revenue by 3–9 months and compress launch margins by 300–1,000 bps versus lab forecasts. Incumbents with existing chemical plants and procurement contracts can blunt price competition through temporary below-cost bids or by leveraging co-pack agreements with fire agencies.

Key catalysts and reversals are regulatory and procurement-driven: published state procurement awards, EPA/state endorsements, and multi-region pilot conversions will likely move the stock in step changes over 3–12 months. Reversal scenarios that would wipe out momentum include IP litigation, published adverse field-efficacy data, or a visible inability to supply at municipal scales — any of which could remove the premium assigned by investors within 30–90 days.

Contrarian read: the market’s optimism underweights go-to-market friction and overweights a straight-line adoption curve. If the product is priced at a premium, expect purchasers to require multi-season proof points; the safest way to capture upside is event-driven exposure around procurement announcements rather than a pure long-biased hold without hedges.

Key Decisions for Investors

• Buy CitroTech (CITR) long-dated calls (12–18 month LEAPS) sized as a 2–3% portfolio conviction trade to capture discrete procurement wins; target 2.5x payoff on successful multi-state rollouts, max loss = premium paid.
• Pair trade: go long CITR / short PRM (dollar-neutral) for a 6–12 month horizon to express share-shift risk — aim for 30–50% relative outperformance if CitroTech secures regional contracts; use a 25% trailing stop on the pair to limit regime risk.
• Sell 6–9 month CITR puts ~15–20% OTM to acquire equity at a discount ahead of expected RFP cycles, keeping cash ready for assignment; worst-case assignment cost should be sized so portfolio downside is <3%.
• Event hedge: buy cheap 3–6 month puts on CITR (or buy inverse ETF/short PRM exposure) ahead of major procurement announcements to protect against negative trial results or supply-failure headlines that can erase premium in 30–90 days.